Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SQLE | Q14534 | 6/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27170334 | 0.91 | KMT2A (0.64) | SQLEKMT2AALOX15MEN1CYP3A4 | |
| SCHEMBL5598148 | 0.91 | KMT2A (0.64) | SQLEKMT2AALOX15MEN1CYP3A4 | |
| SCHEMBL11041167 | 0.91 | KMT2A (0.64) | SQLEKMT2AALOX15MEN1CYP3A4 | |
| SCHEMBL28135732 | 0.89 | KMT2A (0.61) | SQLEKMT2AALOX15MEN1CYP3A4 | |
| SCHEMBL28136505 | 0.89 | KMT2A (0.61) | SQLEKMT2AALOX15MEN1CYP3A4 | |
| SCHEMBL5820930 | 0.77 | KMT2A (0.50) | SQLETSHRKMT2AALOX15MEN1 | |
| SCHEMBL6969622 | 0.77 | — | — | |
| SCHEMBL6964302 | 0.75 | — | — | |
| SCHEMBL9325090 | 0.73 | KMT2A (0.46) | SQLETSHRKMT2AALOX15MEN1 | |
| SCHEMBL10813161 | 0.73 | KMT2A (0.46) | SQLETSHRKMT2AALOX15MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11865094-B2 | Treatment and diagnosis of melanoma | THE ROCKEFELLER UNIVERSITY (US) | 2024-01-09 | — | — | US | disclosed |
| EP-4218935-A1 | LXRBETA AGONIST FOR THE TREATMENT OF CANCER | The Rockefeller University (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116271053-A | Treatment and diagnosis of melanoma | 洛克菲勒大学 | 2023-06-23 | — | — | CN | disclosed |
| EP-3626309-B1 | LXRBETA AGONIST FOR THE TREATMENT OF CANCER | UNIV ROCKEFELLER (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-110037999-B | Treatment and diagnosis of melanoma | 洛克菲勒大学（US） | 2023-01-13 | — | — | CN | disclosed |
| US-20210220306-A1 | TREATMENT AND DIAGNOSIS OF MELANOMA | THE ROCKEFELLER UNIVERSITY | 2021-07-22 | — | — | US | disclosed |
| US-10945978-B2 | Treatment and diagnosis of melanoma | THE ROCKEFELLER UNIVERSITY (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200230090-A1 | TREATMENT AND DIAGNOSIS OF MELANOMA | THE ROCKEFELLER UNIVERSITY (US) | 2020-07-23 | — | — | US | disclosed |
| EP-3626309-A1 | LXRBETA AGONIST FOR THE TREATMENT OF CANCER | The Rockefeller University (US) | 2020-03-25 | — | — | EP | disclosed |
| US-10543183-B2 | Treatment and diagnosis of melanoma | THE ROCKEFELLER UNIVERSITY (US) | 2020-01-28 | — | — | US | disclosed |
| EP-1771407-A1 | 4-HEPTEN-2-YL SALICYLATE AND ITS USE AS A FRAGRANCE INGREDIENT | Givaudan SA (CH) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006007755-A1 | 4-HEPTEN-2-YL SALICYLATE AND ITS USE AS FRAGRANCE INGREDIENT | GIVAUDAN SA (CH) | 2006-01-26 | — | — | WO | disclosed |
| US-5658942-A | Octahydronaphthalene oxime compounds for cholesterol synthesis inhibition | SANKYO COMPANY, LIMITED (JP) | 1997-08-19 | — | — | US | disclosed |
| US-5604256-A | (7-(5-(1,3-DIOXANE-5YL)METHOXYIMINO-2-METHYL-8-(2-METHYLBUTYR -OXY)3-OXO-1,2,3,5,6,7,8,8A-OCTAHYDRO-1-NAPHTHYL)-3-HYDROXY-5 -OXOHEPTANOIC ACID AND SALTS | SANKYO COMPANY, LIMITED (JP) | 1997-02-18 | — | — | US | disclosed |
| EP-0570245-B1 | Octahydronaphthalene oxime derivatives for cholesterol biosynthesis inhibition, their preparation and use | SANKYO CO (JP) | 1996-10-30 | — | — | EP | disclosed |
| US-5403860-A | Octahydronaphthalene oxime compounds for cholesterol synthesis inhibition | SANKYO COMPANY, LIMITED (JP) | 1995-04-04 | — | — | US | disclosed |
| EP-0570245-A2 | Octahydronaphthalene oxime derivatives for cholesterol biosynthesis inhibition, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1993-11-18 | — | — | EP | disclosed |
| EP-0314435-B1 | OCTAHYDRONAPHTHALENE OXIME DERIVATIVES FOR CHOLESTEROL SYNTHESIS INHIBITION, PROCESSES FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | Sankyo Company Limited (JP) | 1993-09-29 | — | — | EP | disclosed |
| US-4997848-A | Enzyme inhibitors | SANKYO COMPANY, LIMITED (JP) | 1991-03-05 | — | — | US | disclosed |
| EP-0314435-A2 | Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition, processes for their preparation and compositions containing them | Sankyo Company Limited (JP) | 1989-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10543183-B2 | Treatment and diagnosis of melanoma | EYA3, BRAF, CD99 | SQLE 4708/4885TSHR 2766/4885KMT2A 1226/4885 |
| US-10945978-B2 | Treatment and diagnosis of melanoma | EYA3, BRAF, CD99 | SQLE 4708/4885TSHR 2766/4885KMT2A 1226/4885 |
| US-11865094-B2 | Treatment and diagnosis of melanoma | EYA3, BRAF, CD99 | SQLE 4708/4885TSHR 2766/4885KMT2A 1226/4885 |
| US-20210220306-A1 | TREATMENT AND DIAGNOSIS OF MELANOMA | EYA3, BRAF, CD99 | SQLE 4708/4885TSHR 2766/4885KMT2A 1226/4885 |
| US-20200230090-A1 | TREATMENT AND DIAGNOSIS OF MELANOMA | EYA3, BRAF, CD99 | SQLE 4708/4885TSHR 2766/4885KMT2A 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.